Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : FDA THRESHOLD: LOWER-RISK BIOTECH INVESTING -- Ignore unavailable to you. Want to Upgrade?

To: opalapril who wrote (15)	10/1/1999 9:43:00 AM
From: Edscharp	Respond to of 75

Opal, I've never attended an FDA meeting and to be honest I'm not inclined to do so now. Aside from the fact that I'm incompetent to decipher the language of clinicians I question whether any hard information would be offered that would be helpful to investors in deciding whether a particular drug is worthy of approval. Do they allow attendees unfettered access to phase III data? Will speakers openly discuss pharmaceuticals and the merits of heretofore unknown and unpublished information? Now, if we could only attend that "closed" meeting......

To: opalapril who wrote (15)	10/2/1999 1:19:00 AM
From: Micro-Selector	Read Replies (1) \| Respond to of 75

Anyone here looked into BSD Medical? I've been following closely since early 1999 and based on my DD and contact with management, current situation looks very promising (I've added some links more complete info): Website: bsdmc.com FDA approval - Recently announced clinical trial for treatment of advanced cervical cancer with the BSD-2000 and radiation therapy was a Phase-III clinical trial. This is now the recommended "first line therapy" with health insurance reimbursement in Holland (approved for health insurance now in several EU countries). Data from this clinical trial currently being reviewed for full FDA approval in US and being published in major medical journal. bsdmc.com bsdmc.com bsdmc.com Expected earnings - To be released in audited annual 10K in November. Hard to estimate as CE Mark which will allow to fill backlog of sales to EU still pending (expected at any time) and FDA approval could generate significant sales. bsdmc.com bsdmc.com Current Sales - Growing interest in the BSD-2000/3D technology, BSD Users Conference in Rotterdam in 9/99 resulting in new orders, plan to release sales backlog figures in near future. If FDA approval received, could significantly boost sales in US. Competition - BSD-2000/3D technology already touted as best hyperthermia treatment available for deep cancers not responding to current therapies. Cancer treatment competitors such as CELN are far from FDA approval. The two companies currently marketing BPH (enlarged prostate) treatments are forced to pay patent license fees to BSD. BSD currently has 34% stake in TherMatrx which is using this patented technology and is close to bringing its own BPH treatment to market. Competitors with alternate technologies (such as PECX) have little market presence and trade at 10X BSD's current price. bsdmc.com bsdmc.com bsdmc.com bsdmc.com bsdmc.com ------------ Whether this is a "hidden gem" or not, remains to be seen. Certainly worth a look though for investors (like me) who prefer "out-of-favor" or "emerging technology" companies. An OTC:BB company that files with SEC, has $2M in cash, is on verge of FDA approval, is major competitor for NASDAQ companies trading at 10X the price (MSON, ULGX, PECX), and has growing presence in market estimated at $4.4 billion (cancer treatment) and $10 billion (BPH treatment) by Year 2000 at least has to qualify as a "major find"!